文献速递其他结缔组织病

血小板在自身免疫、血管病变和纤维化中的作用:对系统性硬化的意义

The role of platelets in autoimmunity, vasculopathy, and fibrosis: Implications for systemic sclerosis.
PubMed 文献 · Semin Arthritis Rheum · 2017-05-23

本文综述血小板在系统性硬化(SSc)发病中的潜在作用。电子检索Medline相关文献,发现实验数据提示血小板在免疫调节、血管病变和纤维化中有多效性作用,与受损内皮和免疫细胞相互作用,并储存参与组织损伤与重塑的生物活性分子。血小板衍生5-羟色胺是SSc的新兴靶点,5-羟色胺阻断正在临床试验中测试,但需更多基础和临床数据才能得出明确结论。

要点

  • 血小板不仅止血,还参与免疫调节、血管病变和纤维化等SSc关键特征。
  • 血小板与受损内皮和免疫细胞相互作用,储存组织损伤与重塑相关生物活性分子。
  • 血小板衍生5-羟色胺是SSc新靶点,5-羟色胺阻断正在临床试验中测试。

核心结论

  • 血小板可能通过激活免疫反应和促进纤维化过程主动参与SSc发病。
  • 需更多基础和临床研究数据才能得出明确结论。

研究设计与样本

  • 电子检索Medline,关键词为血小板、系统性硬化、自身免疫、纤维化、雷诺现象和肺动脉高压。

主要发现

  • SSc中连接血管病变、自身免疫和纤维化的环节仍不明确。
  • 实验数据提示血小板在免疫调节、血管病变、纤维化等SSc关键特征中有多效性作用。
  • 血小板与受损内皮相互作用,可与免疫细胞交互,并储存参与组织损伤和重塑的生物活性分子。
  • SSc动物模型的实验数据进一步支持血小板在SSc发病中的潜在作用。
  • 血小板衍生5-羟色胺是SSc的新靶点,5-羟色胺阻断正在临床试验中测试。

临床怎么用

  • 血小板衍生5-羟色胺通路可作为SSc辅助治疗的潜在靶点,5-羟色胺阻断正在临床试验中测试。

局限性

  • SSc中连接血管病变、自身免疫和纤维化的环节仍不明确。
  • 需更多基础和临床研究数据才能得出明确结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Systemic sclerosis (SSc) is an autoimmune disease characterized by vasculopathy, autoimmunity, and widespread dermal and visceral fibrosis. This article summarizes the current knowledge about the potential contribution of platelets in the disease process and the rationale of targeting platelets as an adjunct treatment for SSc. METHODS: We performed an electronic search (Medline) using the keywords platelets, systemic sclerosis, autoimmunity, fibrosis, Raynaud, and pulmonary arterial hypertension. RESULTS: The link that connects vasculopathy, autoimmunity, and fibrosis in SSc remains obscure. Experimental data suggest that platelets are not solely cell fragments regulating hemostasis but they have a pleiotropic role in several biologic processes including immune regulation, vasculopathy, fibrosis, and all key features of SSc. Platelets interplay with the impaired endothelium, can interact with immune cells, and they are storages of bioactive molecules involved in tissue injury and remodeling. The potential role of platelets in the pathogenesis of SSc is further supported by experimental data in animal models of SSc. Platelet-derived serotonin represents a novel target in SSc and serotonin blockade is currently being tested in clinical trials. CONCLUSION: Platelets may be actively involved in the pathogenesis of SSc by activating immune responses and facilitating the fibrotic process. However, definite conclusions cannot be drawn until more data from both basic and clinical research are available.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Ntelis K, Solomou EE, Sakkas L, et al. The role of platelets in autoimmunity, vasculopathy, and fibrosis: Implications for systemic sclerosis. Semin Arthritis Rheum. 2017. PMID: 28602360. doi:10.1016/j.semarthrit.2017.05.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。